Abstract
Few data are available on either the epidemiology or management of hypertension in older adolescents and young adults, leading to consensus recommendations for the management of hypertension in young adults aged 18 and all adults 60 years and below. The lack of guidance on cardiovascular risk modification is further compounded by limited health insurance coverage and acquisition of poor lifestyle choices, all of which contribute to the development of atherosclerotic disease and other target organ insults. This chapter will review the limited data on hypertension and its management in individuals aged 18–25, as well as the incontrovertible evidence that hypertension and atherosclerosis are progressive conditions that have their origins in the young. Societal interventions such as education regarding appropriate lifestyle choices and expansion of health insurance coverage may be the most appropriate strategies to prevent development of cardiovascular disease later in life.
References
Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial Collaborative Research Group (2003) Diuretic versus alpha-blocker as first-step antihypertensive therapy: final results from the antihypertensive and lipid-lowering treatment to prevent heart attack trial (ALLHAT). Hypertension 42(3):239–246
Appel LJ, Moore TN, Obarzanek E et al (1997) A clinical trial of the effects of dietary patterns on blood pressure. DASH Collaborative Research Group. N Engl J Med 336:1117–1124
Beckett NS, Peters R, Fletcher AE, HYVET Study Group et al (2008) Treatment of hypertension in patients 80 years of age or older. N Engl J Med 358(18):1887–1898
Benavente OR, Coffey CS, Conwit R, SPS3 Study Group et al (2013) Blood-pressure targets in patients with recent lacunar stroke: the SPS3 randomised trial. Lancet 382(9891):507–515
Berenson GS, Srinivasan SR et al (1998) Association between multiple cardiovascular risk factors and atherosclerosis in Children and young adults: the Bogalusa heart study. NEJM 338:1650–1656
Berger JS, Jordan CO et al (2010) Screening for cardiovascular risk in asymptomatic patients. J Am Coll Cardiol 55:1169–1177
Berry JD, Lloyd-Jones DM et al (2007) Framingham risk score and prediction of coronary heart disease death in young adults. Am Heart J 154:80–86
Brenner BM, Cooper ME, de Zeeuw D et al (2001) Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. N Engl J Med 345(12):861–869
Carnethon MR, Gidding SS et al (2003) Cardiorespiratory fitness in young adulthood and the development of cardiovascular disease risk factors. JAMA 290:3092–3100
Cavanaugh-Hussey MW, Berry JD, Lloyd-Jones DM (2008) Who exceeds ATP-III risk thresholds? Systematic examination of the effect of varying age and risk factor levels in the ATP-III risk assessment tool. Prev Med 47:619–623
Centers for Disease Control and Prevention (2013) Vital signs: avoidable deaths from heart disease, stroke, and hypertensive disease–United States, 2001–2010. Morb Mortal Wkly Rep 62:721–727
Chobanian AV, Bakris GL, Black HR et al (2003) The seventh report of the joint National Committee on Preention, detection, evaluation, and treatment of high blood pressure: the JNC 7 report. JAMA 289(19):2560–2573
Cushman WC, Evans GW, Byington RP et al (2010) Effects of intensive blood-pressure control in type 2 diabetes mellitus. N Engl J Med 362(17):1575–1585
Dahlof B, Devereux RB, Kjeldsen SE et al (2002) Cardiovascular morbidity and mortality in the losartan intervention for endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol. Lancet 359(9311):995–1003
Enos WF, Homes RH et al (1953) Coronary disease among United States soldiers killed in action in Korea. JAMA 152:1090–1093
Ford ES, Capewell S (2011) Proportion of the decline in cardiovascular disease mortality due to prevention versus treatment: public health versus clinical care. Annu Rev Public Health 32:5–22
Ford ES, Giles WH et al (2004) The distribution of 10-year risk for coronary heart disease among U.S. adults: findings from the National Health and Nutrition examination Survey III. J Am Coll Cardiol 43:1791–1796
Furman J, Fielder M (2015) 4.5 million young adults have gained coverage since 2010. In: Improving access to care and benefitting our economy. Obama white house archives. Available at https://obamawhitehouse.archives.gov/blog/2015/01/29/45-million-young-adults-have-gained-coverage-2010-improving-access-care-and-benefitt. Last accessed 15 April 2017
Goff DC, Lloyd-Jones DM et al (2014) 2013 ACC/AHA guideline on the assessment of cardiovascular risk. A report of the American College of Cardiology/American Heart Association Task Force on practice guidelines. Circulation 129(2):S49–S73
Gu Q, Burt VL, Dillon CF, Yoon S (2012) Trends in antihypertensive medication use and blood pressure control among united states adults with hypertension – National Health and Nutrition examination Survey, 2001–2010. Circulation 126:2105–2114
Hansson L, Zanchetti A, Carruthers SG et al (1998) Effects of intensive blood-pressure lowering and low-dose aspirin in patients with hypertension: principal results of the hypertension optimal treatment (HOT) randomised trial. Lancet 351(9118):1755–1762
Hypertension Detection and Follow-up Program Cooperative Group (1979) Five-year findings of the hypertension detection and follow-up program, I: reduction in mortality of persons with high blood pressure, including mild hypertension. JAMA 242(23):2562–2571
Intersalt Cooperative Research Group (1998) Intersalt: an international study of electrolyte excretion and blood pressure. Results for 24 hour urinary sodium and potassium excretion. BMJ 297:319–328
IPPPSH Collaborative Group (1985) Cardiovascular risk and risk factors in a randomized trial of treatment based on the beta-blocker oxprenolol: the international prospective primary prevention study in hypertension (IPPPSH). J Hypertens 3(4):379–392
James PA, Oparil S et al (2014) 2014 evidence-based guideline for the Management of High Blood Pressure in adults: report from the panel members appointed to the eighth join National Committee. JAMA 311(5):507–5020
JATOS Study Group (2008) Principal results of the Japanese trial to assess optimal systolic blood pressure in elderly hypertensive patients (JATOS). Hypertens Res 31(12):2115–2127
Klahr S, Levey AS, Beck GJ et al (1994) The effects of dietary protein restriction and blood-pressure control on the progression of chronic renal disease. N Engl J Med 330(13):877–884
Lewington S (2002) Age-specific relevance of usual blood pressure to vascular mortality: a meta-analysis. Lancet 360(9349):1903
Lewis EJ, Hunsicker LG, Bain RP, Rohde RD (1993) The effect of angiotensin-converting-enzyme inhibition on diabetic nephropathy. N Engl J Med 329(20):1456–1462
Lewis EJ, Hunsicker LG, Clarke WR et al (2001) Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes. N Engl J Med 345(12):851–860
Lloyd-Jones DM, Leip EP, Larson MG et al (2006) Prediction of lifetime risk for cardiovascular disease by risk factor burden at 50 years of age. Circulation 113:791–798
McGill HC, McMahan A, Gidding SS (2008) Preventing heart disease in the 21st century: implications of the Pathobiological determinants of atherosclerosis in youth (PDAY) study. Circulation 117:1216–1227
McNamara JJ, Molot MA et al (1971) Coronary artery disease in combat casualties in Vietnam. JAMA 216:1185–1187
Medical Research Council Working Party (1985) MRC trial of treatment of mild hypertension: principal results. Br Med J (Clin Res Ed) 291(6488):97–104
Murphy SL, Xu J, Kochanck KD (2013) Deaths: final data for 2010. Natl Vital Stat Rep 61(4):1–117
National Center for Health Statistics (2016) Health, United States, 2015: with special feature on racial and ethnic health disparities. Hyattsville, Maryland. Available at https://www.cdc.gov/nchs/hus/contents2015.htm#trendtables. Last accessed 15 April 2017
Ogihara T, Saruta T, Rakugi H et al (2010) Target blood pressure for treatment of isolated systolic hypertension in the elderly: valsartan in elderly isolated systolic hypertension study. Hypertension 56(2):196–202
Ostchega Y, Yoon SS, Hughes J, Louis T (2008) Hypertension awareness, treatment, and control – continued disparities in adults: United States. NCHS Data Brief 2005–2006:1–8
Patel A, MacMahon S, Chalmers J et al (2007) Effects of a fixed combination of perindopril and indapamide on macrovascular and microvascular outcomes in patients with type 2 diabetes mellitus (the ADVANCE trial): a randomised controlled trial. Lancet 370(9590):829–840
Ruggenenti P, Perna A, Gherard G, REIN Study Group et al (1999) Renoprotective properties of ACE-inhibition in non-diabetic nephropathies with non-nephrotic proteinuria. Lancet 354:359–364
Selassie A, Wagner CS, Laken ML et al (2011) Progression is accelerated from prehypertension to hypertension in blacks. Hypertension 58:579–587
SHEP Cooperative Research Group (1991) Prevention of stroke by antihypertensive drug treatment in older persons with isolated systolic hypertension: final results of the systolic hypertension in the elderly program (SHEP). JAMA 265(24):3255–3264
Siu AL, U.S. Preventive Services Task Force (2015) Screening for high blood pressure in adults: U.S. preventive services task force recommendation statement. Ann Intern Med 163(10):778–787
Staessen JA, Fagard R, Thijs L et al (1997) The systolic hypertension in Europe (Syst-Eur) trial investigators. Randomised double-blind comparison of placebo and active treatment for older patients with isolated systolic hypertension. Lancet 350(9080):757–764
Steinberger J, Daniels SR, Hagberg N et al (2016) Cardiovascular health promotion in Children: challenges and opportunities for 2020 and beyond. A scientific statement from the American Heart Association. Circulation 134(12):e236–e255
Strong JP, McGill HC (1962) The natural history of coronary atherosclerosis. Am J Pathol 40:37–49
The SPRINT Research Group (2015) A randomized trial of intensive versus standard blood-pressure control. N Engl J Med 373:2103–2116
Towfighi A, Markovic D, Ovbiagele B (2011) Recent patterns of sex-specific midlife stroke hospitalization rates in the United States. Stroke 42:3029–3033
Uberoi N, Finegold K, Gee E (2016) Health insurance coverage and affordable care act, 2010-2106. Department of Health & Human Services, ASPE Issue Brief 1–14. Available at https://aspe.hhs.gov/sites/default/files/pdf/187551/ACA2010-2016.pdf. Last accessed 15 April 2017
UK Prospective Diabetes Study Group (1998) Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38. BMJ 317(7160):703. BMJ 1999 Jan 2;318(7175):29
US Census Bureau (2012) Health insurance historical tables – HIB series. Washington, DC, US Department of Commerce, US Census Bureau. Available at https://www.census.gov/topics/health/health-insurance/data/tables.2012.html. Last accessed 15 April 2017
VA Cooperative Study Group on Antihypertensive Agents (1967) Effects of treatment on morbidity in hypertension. Results in patients with diastolic blood pressures averaging 115 through 129 mm hg. JAMA 202(11):1028–1034
Vasan RS, Beiser A, Seshadri S et al (2002) Residual lifetime risk for developing hypertension in middle-aged women and men: the Framingham heart study. JAMA 287:1003–1010
Ventura HO, Lavie CJ (2011) Antihypertensive therapy for prehypertension: relationship with cardiovascular outcomes. JAMA 305(9):940–941
Verdecchia P, Staessen JA, Angeli F et al (2009) Usual versus tight control of systolic blood pressure in non-diabetic patients with hypertension (cardio-sis): an open-label randomised trial. Lancet 374(9689):525–533
Winegarden CR (2005) From “prehypertension” to hypertension? Additional evidence. Ann Epidemiol 15:720–725
Wright JT Jr, Bakris G, Greene T et al (2002) Effect of blood pressure lowering and antihypertensive drug class on progression of hypertensive kidney disease: results from the AASK trial. JAMA 288(19):2421–2431
Yusuf S, Teo KK, Pogue J et al (2008) Telmisartan, ramipril, or both in patients at high risk for vascular events. N Engl J Med 358(15):1547–1559
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Section Editor information
Rights and permissions
Copyright information
© 2017 Springer International Publishing AG
About this entry
Cite this entry
Anderson, A.E. (2017). Hypertension in Older Adolescents and Young Adults. In: Flynn, J., Ingelfinger, J., Redwine, K. (eds) Pediatric Hypertension. Springer, Cham. https://doi.org/10.1007/978-3-319-31420-4_52-1
Download citation
DOI: https://doi.org/10.1007/978-3-319-31420-4_52-1
Received:
Accepted:
Published:
Publisher Name: Springer, Cham
Print ISBN: 978-3-319-31420-4
Online ISBN: 978-3-319-31420-4
eBook Packages: Springer Reference MedicineReference Module Medicine
Publish with us
Chapter history
-
Latest
Hypertension in Older Adolescents and Young Adults- Published:
- 27 March 2022
DOI: https://doi.org/10.1007/978-3-319-31420-4_52-2
-
Original
Hypertension in Older Adolescents and Young Adults- Published:
- 26 April 2017
DOI: https://doi.org/10.1007/978-3-319-31420-4_52-1